Literature DB >> 8422221

A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.

D W Black1, R Wesner, W Bowers, J Gabel.   

Abstract

Seventy-five outpatients with moderate to severe panic disorder were randomly assigned to receive 8 weeks of fluvoxamine, cognitive therapy, or placebo. Fifty-five patients completed the treatment protocol. Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables. Subjects receiving cognitive therapy also showed improvement, but this improvement did not significantly differ from the experience of the placebo-treated group for most comparisons. Fluvoxamine was superior to cognitive therapy for many ratings, but cognitive therapy was not superior to fluvoxamine on any rating. Fluvoxamine also produced improvement earlier than cognitive therapy. At the main comparison point (week 4), 57% (13/23) of patients receiving fluvoxamine were rated moderately improved or better vs 40% (8/20) of the group given cognitive therapy and 22% (5/23) of the placebo-treated group. At that point, 43% (10/23) of the fluvoxamine recipients vs 25% (5/20) of cognitive therapy and 4% (1/23) of placebo recipients were free of panic attacks.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422221     DOI: 10.1001/archpsyc.1993.01820130046008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  23 in total

1.  Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.

Authors:  M R Mavissakalian; J K Schmier; J A Flynn; D A Revicki
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

Review 2.  Panic disorder.

Authors:  M H Rapaport; C Barrett
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

3.  Placebo: a potent but misunderstood psychotrope.

Authors:  Y D Lapierre
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

4.  Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care.

Authors:  D M Sharp; K G Power; R J Simpson; V Swanson; J A Anstee
Journal:  Br J Gen Pract       Date:  1997-03       Impact factor: 5.386

Review 5.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

6.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

8.  Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials.

Authors:  Stefan G Hofmann; Jasper A J Smits
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

9.  The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons.

Authors:  Pim Cuijpers; Marit Sijbrandij; Sander L Koole; Gerhard Andersson; Aartjan T Beekman; Charles F Reynolds
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

Review 10.  Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials.

Authors:  Joseph K Carpenter; Leigh A Andrews; Sara M Witcraft; Mark B Powers; Jasper A J Smits; Stefan G Hofmann
Journal:  Depress Anxiety       Date:  2018-02-16       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.